CBP-501

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameCBP-501
Drug Alias NameCBP-501Cdc-25C-phosphatase (211-221)
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionCheckpoint kinase 2 inhibitorsCheckpoint kinase 1 inhibitors
TargetsCheckpoint kinase 2Checkpoint kinase 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCanbas Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCanbas Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMesothelioma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A